Financial Review: INVO Bioscience (NASDAQ:INVO) and Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Nyxoah and INVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
INVO Bioscience	-122.79%	N/A	-36.94%

Risk and Volatility

Nyxoah has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Insider and Institutional Ownership

12.0% of INVO Bioscience shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 3.5% of INVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Nyxoah and INVO Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.52 million	43.54	-$46.77 million	($1.95)	-2.96
INVO Bioscience	$5.77 million	1.41	-$8.03 million	N/A	N/A

INVO Bioscience has higher revenue and earnings than Nyxoah.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nyxoah and INVO Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	4	0	3.00
INVO Bioscience	0	0	0	0	0.00

Nyxoah presently has a consensus target price of $14.50, suggesting a potential upside of 150.87%. Given Nyxoah’s stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than INVO Bioscience.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About INVO Bioscience

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.